drugset / Trial / NCT01574651

The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01574651

Phase 3 Completed 934 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the efficacy and safety of QVA149 compared to tiotropium plus formoterol in patients with moderate to severe COPD.

Timeline

Start
2012-05
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Formoterol Other / unclassified 12 ug Inhaled
Subject QVA149 Other / unclassified 50 ug Inhaled
Subject QVA149 Other / unclassified 110 ug Inhaled
Comparator Tiotropium Other / unclassified 18 ug Inhaled